Neuphoria Therapeutics (NEUP) Q1 2026 Earnings Report

Revenue: 0 for QQ1 2026 (no reported revenue). Gross Profit: N/A. Operating Income: -$5,652,689; YoY -136.12%, QoQ -147.20%. Net Income: -$9,906,504; YoY -256.61%, QoQ -187.96%. EBITDA: -$5,652,689. EPS: -$4.41; YoY ~-22,631.96%, QoQ ~-9,268.40%. R&D Expenses: $3,785,649. G&A Expenses: $1,867,040. D&A: $165,792. Stock-Based Compensation: $111,277. Total Operating Expenses: $5,652,689. CFO: -$3,794,648. Free Cash Flow: -$3,794,648. Cash at end of period: ~$13.73 million. Total Assets: $27.34 million. Total Liabilities: $14.83 million. Total Stockholders’ Equity: $12.51 million. Net Debt: -$13.56 million (net cash). Key balance sheet drivers include Goodwill $8.67 million and Intangible Assets $4.64 million (Total Goodwill & Intangibles: $13.31 million).